A gene which plays a key role in activating the immune system - andperhaps also in spurring on HIV, the virus that causes AIDS - has been discovered and cloned by researchers at Israel's Weizmann Institute of Science.
The gene, called NIK, helps remove a molecular "brake" that keeps the immune system in check. Its discovery could lead to the development of drugs to regulate the immune system in a variety of diseases. Drugs that block NIK's effects might be designed to inhibit unwanted immune responses in autoimmune diseases such as juvenile diabetes or rheumatoid arthritis. Conversely, drugs that enhance NIK's effects might be designed to augment immunity in immune deficiency diseases.
NF-kB In Immune Response Scientists have known for some two decades that a protein called nuclear factor-kB is a key molecule in the immune reponse. NF-kB belongs to the class of proteins known as transcription factors, which "switch on" certain genes and cause specific reactions to take place. In particular, NF-kB switches on several genes involved in immune and inflammatory responses to disease and infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze